Insider Selling: Surface Oncology, Inc. (NASDAQ:SURF) CEO Sells 10,594 Shares of Stock

Surface Oncology, Inc. (NASDAQ:SURFGet Rating) CEO Robert W. Ross sold 10,594 shares of the company’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $1.72, for a total value of $18,221.68. Following the completion of the sale, the chief executive officer now owns 99,906 shares in the company, valued at $171,838.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Surface Oncology Price Performance

Surface Oncology stock traded down $0.02 on Friday, reaching $1.78. The company’s stock had a trading volume of 857,629 shares, compared to its average volume of 717,498. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.42 and a current ratio of 9.42. The company has a market cap of $97.21 million, a price-to-earnings ratio of -1.38 and a beta of 1.60. The business’s fifty day moving average price is $1.80 and its 200 day moving average price is $2.48. Surface Oncology, Inc. has a twelve month low of $1.37 and a twelve month high of $8.38.

Surface Oncology (NASDAQ:SURFGet Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.61. Surface Oncology had a negative return on equity of 47.56% and a negative net margin of 182.63%. The company had revenue of $30.00 million for the quarter. Equities analysts expect that Surface Oncology, Inc. will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Surface Oncology

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Surface Oncology during the first quarter valued at $27,000. Formidable Asset Management LLC acquired a new position in shares of Surface Oncology during the first quarter valued at $33,000. Delphia USA Inc. acquired a new position in shares of Surface Oncology during the first quarter valued at $36,000. Forefront Analytics LLC acquired a new position in shares of Surface Oncology during the first quarter valued at $62,000. Finally, Eagle Rock Investment Company LLC acquired a new position in shares of Surface Oncology during the fourth quarter valued at $105,000. Institutional investors and hedge funds own 70.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Jonestrading reiterated a “buy” rating and issued a $12.00 price target on shares of Surface Oncology in a research report on Sunday, June 5th.

About Surface Oncology

(Get Rating)

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.

See Also

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.